Prostate

Prostate cancer mortality has declined by approximately 50% since 1993 because of improvements in detection and treatment. However, prostate cancer remains a key challenge in men’s health as a new patient is diagnosed every 2 minutes, and prostate cancer remains the second-leading cause of cancer death in American men.¹ Quest Diagnostics remains committed to providing a comprehensive menu of testing offerings, from screening to survivorship, to support patients and their physicians.

The Guideline Based Hereditary Cancer Panel includes 32 genes associated with a broad spectrum of hereditary cancers. This can include, but is not limited to, cancers of the prostate, colon, endometrium, stomach, urinary tract, ovary, pancreas, breast, rectum, and other tissues. Individuals with a positive result (pathogenic or likely pathogenic variant detected) have an increased risk for developing certain cancers relative to that of the general population.

Quest Diagnostics offers a full range of PSA tests to support early detection of prostate cancer. Serial monitoring of PSA levels at regular intervals, along with physical examinations and other tests, may help to detect new or recurrent prostate cancer.

A more effective test to stratify patients with elevated PSA levels, IsoPSA^® assesses structural isoforms of PSA correlated with malignancy. IsoPSA is an accurate, simple, and proven addition to the screening tests available for prostate cancer.

The AmeriPath^® national network of board-certified pathologists provides comprehensive pathology services utilizing state-of-the-art technologies including immunohistochemistry and molecular diagnostics.

We are an industry leader in prostate pathology expertise. Combined with our comprehensive test menu and advanced technology, our expertise ensures you receive prompt, accurate information for making diagnostic, prognostic, and therapeutic decisions.

Quest Diagnostics maintains an up-to-date and robust selection of immunohistochemical stains to gather diagnostic insight for the patient, including prostate triple stain, comprising P504S, HMW Keratins, and P63.

Pathologic evaluation of prostate cancer can be challenging, especially when there is a small focus of cancer. Because benign prostate glands contain basal cells and cancerous glands do not, differential staining of basal cells in the prostate may be useful for diagnosis. This test uses a combination of several antibodies (applied to a single slide) that differentially stain for basal cells and neoplastic cells in the prostate: P504S stains prostate adenocarcinoma, whereas p63 and the high molecular weight cytokeratins stain benign prostate basal epithelial cells.

This combination may also help differentiate prostate cancer from precancerous lesions such as prostatic intraepithelial neoplasia (PIN), especially when tissue is limited.

LiquidSEQ™ is a liquid biopsy for treatment selection. It provides a comprehensive molecular profile—including 523 genes associated with a broad spectrum of solid tumor cancers—that assesses the DNA for single nucleotide variants (SNVs), copy number variants (CNVs), and fusions along with genomic signatures, microsatellite instability (MSI), and tumor mutation burden (TMB). This panel would be used if the clinician desires a comprehensive analysis of a patient’s genetic profile from the patient’s blood in the event tissue is not available or insufficient. This panel contains clinically actionable genes as well as emerging genes.

Precision medicine is an emerging approach for disease prevention and treatment that takes individual variability into account. This next-generation sequencing (NGS) panel, along with the computational resources and tools that process and analyze the data, allows the characterization of individual patients and tumor types. Guidelines exist for using results from many of these genes for selection of FDA-approved therapies.

Solid TumorSEQ™ provides a comprehensive molecular profile from biopsy tissue, including 523 genes associated with a broad spectrum of solid tumor cancers, and assesses the DNA and RNA for SNVs, CNVs, fusions, and splice variants along with genomic signatures, microsatellite instability (MSI), and tumor mutation burden (TMB). This panel would be used if a clinician desires a comprehensive analysis of a patient’s genetic profile from tumor tissue. This panel contains clinically actionable genes as well as emerging genes chosen based on alignment to guidelines, drug labels and clinical trials across multiple solid tumor types.

Haystack MRD^®

Sensitivity matters when looking for the lowest levels of disease, such as residual disease after surgery or in response to adjuvant chemotherapy. Haystack MRD minimizes false negatives by detecting ultralow levels of circulating tumor DNA (ctDNA), providing confidence in therapeutic decisions.⁴